| Unique ID issued by UMIN | UMIN000034026 |
|---|---|
| Receipt number | R000038792 |
| Scientific Title | Odefsey Drug Use Results Survey |
| Date of disclosure of the study information | 2018/09/20 |
| Last modified on | 2020/03/06 17:41:32 |
Odefsey Drug Use Results Survey
Odefsey Drug Use Results Survey
Odefsey Drug Use Results Survey
Odefsey Drug Use Results Survey
| Japan |
HIV/AIDS
| Infectious disease |
Others
NO
To confirm the safety and efficacy of Odefsey under actual use conditions in patients with HIV infection.
Safety,Efficacy
Safety (ADR)
Effectiveness(Changes in HIV-RNA level, Changes in CD4 lymphocyte count)
Observational
| Not applicable |
| Not applicable |
Male and Female
Patients with HIV infection who received Odefsey
NA
80
| 1st name | Toshiya |
| Middle name | |
| Last name | Kato |
Janssen Pharmaceutical K.K.
Safety Risk Management Dept.
101-0065
5-2, Nishi-Kanda 3-chome, Chiyoda-ku, Tokyo
03-4411-5478
tkato1@its.jnj.com
| 1st name | Masayuki |
| Middle name | |
| Last name | Takagishi |
Janssen Pharmaceutical K.K.
Safety Risk Management Dept.
101-0065
5-2, Nishi-Kanda 3-chome, Chiyoda-ku, Tokyo
03-4411-5464
mtakagis@its.jnj.com
Janssen Pharmaceutical K.K.
Janssen Pharmaceutical K.K.
Profit organization
Janssen Pharmaceutical K.K.
5-2, Nishi-Kanda 3-chome, Chiyoda-ku, Tokyo
03-4411-5464
mtakagis@its.jnj.com
NO
| 2018 | Year | 09 | Month | 20 | Day |
Unpublished
Enrolling by invitation
| 2018 | Year | 08 | Month | 27 | Day |
| 2018 | Year | 09 | Month | 20 | Day |
Prospective study
| 2018 | Year | 09 | Month | 04 | Day |
| 2020 | Year | 03 | Month | 06 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000038792